MICHELLE MERCADO: Open Payments
NPI 1841473816 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$645 in 27 payments from 8 companies in 2025. Trend: 2023 $653 · 2024 $734 · 2025 $645
Food & beverage: $645
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $178 |
| Alkermes, Inc. | 7 | $138 |
| Janssen Pharmaceuticals, Inc | 4 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Lundbeck LLC | 3 | $43 |
| ABBVIE INC. | 1 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: INGREZZA, LYBALVI, INVEGA SUSTENNA, CAPLYTA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, VRAYLAR, COBENFY.
Industry payments across TX — which companies pay providers there.
